Section Arrow
Quote
ALPN.NASDAQ
- Alpine Immune Sciences
Quotes are at least 15-min delayed:2024/05/14 05:11 EDT
Last
 64.96
+0.02 (+0.03%)
Day High 
64.96 
Prev. Close
64.94 
1-M High
64.94 
Volume 
2.97M 
Bid
63.94
Ask
65.96
Day Low
64.92 
Open
64.94 
1-M Low
64.15 
Market Cap 
4.26B 
Currency USD 
P/E -- 
%Yield 0 
10-SMA 64.68 
20-SMA 64.6 
50-SMA 49.71 
52-W High 64.96 
52-W Low 8.11 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.64/-1.68
Enterprise Value
4.27B
Balance Sheet
Book Value Per Share
4.85
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
58.88M
Operating Revenue Per Share
0.44
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
NVAXNovavax13.11+4.23+47.64%-- 
DNAGinkgo Bioworks Holdings0.8407+0.0798+10.49%-- 
ACIUAC Immune SA3.3+0.99+42.86%-- 
JAGXJaguar Health0.290795-0.001305-0.45%-- 
TVGNTevogen Bio Holdings1+0.0155+1.57%-- 
Quotes are at least 15-min delayed：2024/05/14 05:11 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Alpine Immune Sciences Inc is a clinical-stage biopharmaceutical company dedicated to discovering and developing protein-based immunotherapies to treat autoimmune and inflammatory diseases. Its approach includes a proprietary scientific platform that converts native immune system proteins into differentiated, multi-targeted therapeutics. Its pipeline candidates are; ALPN-303, or povetacicept, is a dual antagonist of the B cell activating factor, or BAFF, and a proliferation-inducing ligand, or APRIL, cytokines, which play key roles in the activation, development, and survival of B cells, and ALPN-101, or acazicolcept, is a dual Inducible T cell Costimulator, or ICOS, and CD28 antagonist intended for the treatment of autoimmune and inflammatory diseases.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.